Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 13, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and transactions related to employee share plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and equity transactions rather than financial performance.
Material Changes
The material changes reported are specific to equity holdings and employee compensation plans:
- Director Acquisition: Mr. J D Coombe acquired 20 Ordinary Shares in total on November 11, 2003, through the ShareReward Plan at a price of £12.87 per share. This included 10 shares via personal contribution and 10 shares via company matching.
- Trust Transfers: Abacus (GSK) Trustees Limited transferred a total of 15,315 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991. This consisted of two separate transfers of 12,584 and 2,731 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory disclosure of share transactions.
Key Facts for Investor Verification
- Verify the total number of shares transferred from the GSK Trust to the 1991 Employee Share Option Plan (15,315 shares).
- Confirm the purchase price of £12.87 per share for Mr. Coombe's acquisition under the ShareReward Plan.
- Note that Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in the GSK Trust as potential beneficiaries alongside other employees.